Skip to main content

Accustem Sciences Inc. (ACUT)

New York Stock Exchange Healthcare BiotechnologyView data quality →
34.8Poor

ValueMarkers Composite Index

Top 1%#44,057 of 44,714

DCF data not available

Piotroski
1/9
Weak
Beneish
-
Altman
-396.10
Distress
DCF Value
-
N/A
ROIC
53.0%
Strong
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Accustem Sciences Inc. (ACUT) — VMCI valuation read

Composite valuation read on ACUT: VMCI 35/100 against a Healthcare sector median of 50. The 15-point below-median print is the headline number for Accustem Sciences Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for ACUT: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on ACUT: ACUT trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -2.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

ACUT fell 3.1% over the trailing 7 days, with a -15.2% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ACUT’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.